Novartis’s Luxturna Deal Expands Gene Therapy Ambitions

 
• By Sten Stovall
Eye
Novartis Licensed Spark's Luxturna Ex-US For Rare Inherited Blindness • Source: Shutterstock

More from Deals

More from Business